Navigation Links
Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
Date:10/29/2010

SHPGY"> SHPGY) the global specialty biopharmaceutical company, announces results for the three months to September 30, 2010.

Financial Highlights Q3 2010(2) Product sales(1) $794 million +32% Total revenues $874 million +31% Non GAAP operating income $298 million +123% US GAAP operating income $156 million +70% Non GAAP diluted earnings per ADS $1.16 +138% US GAAP diluted earnings per ADS $0.52 +59%

(1) Product sales excluding ADDERALL XR ("Core Product Sales") were up 31% to $694 million. Core Product Sales at constant exchange rates ("CER"), computed by restating 2010 results using average 2009 foreign exchange rates, were up 34%.

(2) Percentages compare to equivalent 2009 period.

Angus Russell, Chief Executive Officer, commented:

"We delivered another outstanding set of results this quarter with strong revenue growth and operating leverage driving increases in Non GAAP earnings. This continued excellent performance demonstrates the overall strength of Shire's business and the sustained execution of our strategy.

In ADHD, VYVANSE sales are up 17% and the number of new physicians prescribing INTUNIV continues to increase.

Sales of REPLAGAL have increased by 91% as we respond to the great need of our Fabry patients; we estimate that our global market share now exceeds 60%. Only seven months into the initial launch of our treatment for Gaucher patients, around 1,000 patients are now on VPRIV, representing a 16% global market share.

We've made progress in several significant programs in our research and development pipeline, including investigative uses of VYVANSE for adjunctive therapy in patients with Major Depressive Disorder ("MDD"). We've also recently completed our acquisition of Movetis NV, bringing the approved product RESOLOR to our gastro-intestinal ("GI") portfolio, and announced the in-licence from Acceleron of a Phase 2 orphan drug for Duchenne Muscular Dystrophy.

Alongside del
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
2. Reportlinker Adds Shire plc: PharmaVitae Profile
3. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
4. Shire plc - Statement re ProAmatine
5. Shire Proposes to Expand Specialist Gastrointestinal Portfolio
6. Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.
7. Shire Receives CHMP Positive Opinion for VPRIV(TM) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease in the European Union
8. Shire plc Appoints Two New Board Directors
9. INTUNIV(TM) - Shire Files Suit Against Anchen Pharmaceuticals, Inc. and Anchen, Inc.
10. Shire Receives 2010 Corporate Award From the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for Injection)
11. INTUNIV(TM) - Shire Files Suit Against Actavis Elizabeth LLC and Actavis Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Ireland , September 18, 2014 ... and Markets ( http://www.researchandmarkets.com/research/czvg3s/biocompatible ) has ... "Biocompatible Materials - Global Strategic Business ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,This report analyzes ... in US$ Million by the following ...
(Date:9/18/2014)... Research and Markets has announced ... Report 2014" report to their offering. ... a professional and in-depth study on the current state ... report provides a basic overview of the industry including ... albumin market analysis is provided for the international markets ...
(Date:9/18/2014)... 18, 2014  Neogen Corporation (Nasdaq: NEOG ... strategic agreement with Merck Animal Health to market Neogen,s ... The Igenity Dairy Heifer Program consists of genomic tests ... genetic potential of replacement dairy heifers. The genomic tests ... and is an excellent tool in the decision-making process ...
(Date:9/18/2014)... MA (PRWEB) September 18, 2014 ... Molecule Sequencing (tSMS™) technology, announced today the closing ... of investment, led by Genomic Diagnostic Technologies, will ... and diagnostic applications. , Founded in March 2013 ... and Bioinformatics Analyst at Helicos BioSciences, SeqLL has ...
Breaking Biology Technology:Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3Merck Animal Health to market Neogen's dairy genomic program 2SeqLL Closes Series-A Funding Round for Expansion of Single Molecule Sequencing 2
... ... ... ... ...
... ... ... ... ...
... ... as an extension of a company,s clinical team to deliver greater visibility and control ... ... www.cleartrial.com ), the leading provider of Clinical Trial Operations (CTO) software, today unveiled the ...
Cached Biology Technology:AstraZeneca Outlines Principles for Product-Related Online Communications 2AstraZeneca Outlines Principles for Product-Related Online Communications 3AstraZeneca Outlines Principles for Product-Related Online Communications 4AstraZeneca Outlines Principles for Product-Related Online Communications 5AstraZeneca Outlines Principles for Product-Related Online Communications 6AstraZeneca Outlines Principles for Product-Related Online Communications 7febit's miRBase 14 Geniom-Biochip Now With 58 Additional New Sequences Available for Cancer Research 2febit's miRBase 14 Geniom-Biochip Now With 58 Additional New Sequences Available for Cancer Research 3febit's miRBase 14 Geniom-Biochip Now With 58 Additional New Sequences Available for Cancer Research 4febit's miRBase 14 Geniom-Biochip Now With 58 Additional New Sequences Available for Cancer Research 5febit's miRBase 14 Geniom-Biochip Now With 58 Additional New Sequences Available for Cancer Research 6ClearTrial Launches New Service to Bring Speed and Accuracy in Clinical Trial Planning Within Reach of Smaller Biopharma Companies 2ClearTrial Launches New Service to Bring Speed and Accuracy in Clinical Trial Planning Within Reach of Smaller Biopharma Companies 3
(Date:9/17/2014)... -- "Nature has developed, very cleverly, some lessons on ... optical design," said Joseph Shaw, director of the Optical ... surfaces and structures at the nanoscale, we,ll discover them." ... Diego in August during a conference called "The Nature ... Rongguang Liang of the University of Arizona College of ...
(Date:9/17/2014)... Social Evolution and Yale University offers compelling support for ... can partially predict the likelihood of being diagnosed with ... in life. The study analyzed medical records of 1.75 ... to 30 years, and adjusted for almost all other ... the Proceedings of the Royal Society, London B ...
(Date:9/17/2014)... Spanish researchers have obtained the first partial genome sequence ... pig found at the site of the Montsoriu Castle ... pig is closely related to today,s Iberian pig. Researchers ... with modern Iberian pigs. , The study, published in ... of pig species, and particularly on that of the ...
Breaking Biology News(10 mins):Nature's designs inspire research into new light-based technologies 2Nature's designs inspire research into new light-based technologies 3Size at birth affects risk of adolescent mental health disorders 2Size at birth affects risk of adolescent mental health disorders 3Iberian pig genome remains unchanged after 5 centuries 2
... biochemists at the University of Washington two years ago launched ... solve medical problems. The game, Foldit, turns one of the ... reminiscent of Tetris. Thousands of people have now played a ... stack colored blocks or rescue a princess. Results published ...
... Calif.Our belief as to whether we will likely succeed or ... losingdirectly affects the levels of neural effort put forth in ... brain-imaging study by neuroscientists at the California Institute of Technology ... A. Andersen, the James G. Boswell Professor of Neuroscience at ...
... understand life in your own backyard? Cities and suburbs form their ... an integral component, like trees in a forest or coral in ... in cities and the amount of paved surfaces in the United ... thrive in the city? Urban Ecosystem Ecology is a new ...
Cached Biology News:Gaming for a cure: Computer gamers tackle protein folding 2Gaming for a cure: Computer gamers tackle protein folding 3Gaming for a cure: Computer gamers tackle protein folding 4Caltech: Gain and loss in optimistic versus pessimistic brains 2Caltech: Gain and loss in optimistic versus pessimistic brains 3The real urban jungle 2
... The BioGenex VISION Sytem is a ... comes with proprietary digital imaging and ... digital image acquisition, analysis, archving/retrieval and ... a state-of-the-art digital imaging system that ...
... -mr agarose is specifically for ... endoosmosis, and is recommended for ... weight proteins or complexes that ... of molecular sieving in polyacrylamide ...
... agarose is used for second-dimension SDS-PAGE ... in place in PROTEAN Plus cells. ... to allow monitoring of electrophoresis runs. ... agarose in 1x Tris, glycine, SDS, ...
The Trans-Blot Plus gel and cassette assembly tray is used to hold the Trans-Blot Plus gel holder cassette, buffer, and other materials for the gel and membrane sandwich during their assembly....
Biology Products: